The present invention relates to the field of pulsed high power lasers and the problem of delivering their output through optical fibers and especially for use in tissue ablation with the energy transmitted through those fibers.
Delivery of high pulsed laser power through optical fibers is widely used for ablation of tissue or other targets. For such ablation procedures, ultra-violet (UV) light has many advantages, as it is well absorbed by biological matter and organic compounds. Rather than burning or cutting material, the UV laser adds enough energy to disrupt the molecular bonds of the surface tissue, which effectively disintegrates into the air in a tightly controlled manner through ablation rather than burning. The laser energy is also strongly absorbed and leads to sharp local elevation of temperature and results in generation of strong mechanical forces leading to photo-acoustic and photo-thermal ablation. Thus lasers emitting in the ultraviolet have the useful property that they can remove exceptionally fine layers of surface material with almost no heating or change to the remainder of the surrounding material which is left intact. Excimer lasers emitting at 308 nm (XeCl) are commonly used. However, such lasers are bulky, require careful maintenance and frequent calibration, and the beam quality is poor and may not be stable. Third harmonic, Q-switched Nd:YAG lasers emitting at 355 nm have also been used for such UV ablation procedures.
In order to obtain effective tissue ablation, fluencies above a certain threshold are required, and high peak power pulses, of the order of 50 mJ/mm2 in pulses of down to the 10 nsec range are generally desired. The delivery of such fluences is very challenging for the optical fibers, and can lead to damage at the entrance or exit facets of the fiber, or in the bulk of the fiber by selective heating, plasma generation, self-focussing or the generation of cracks at the exit facet. In order to overcome the challenge of this kind of damage, methods have been proposed in the prior art of taking the high quality beam emitting by the laser, and of homogenizing the beam before input to the fiber, to eliminate “hot spots”. Some such methods that have been proposed include:
(i) The laser is coupled to the optical fiber using a diffractive optical element (DOE) and a coupling lens. The DOE homogenizes the beam spatial energy density and eliminates “hot spots” of the laser. The DOE can form different shapes, including a square, a circle, rectangular, as adapted to the different shapes of the input plane of a bundle of fibers. Different coupling lenses and different distances between the DOE and the coupling lens have been used, in order to obtain different spot sizes.
(ii) A micro-lens array is used to achieve a homogenized spot. More than one array can also be used in order to achieve better homogeneity and to avoid hot spots due to beamlet interference. The size and shape of the spot can be manipulated by varying the pitch size and the coupling lens focal length. Such a micro-lens array homogenizer for executing the coupling of high peak power laser pulses into optical fibers, has been described in an article by T. Schmidt-Uhlig et al, entitled “New Simplified Coupling Scheme for the Delivery of 20 MW Nd:YAG Laser Pulses by Large Core Optical Fibers”, published in Applied Physics B, Lasers and Optics, Vol. 72, pages 183-186 (2001).
(iii) Use of a multimode fiber in order to homogenize the beam energy density. A positive lens is used to couple the laser beam into the homogenizer fiber, and a second positive lens is used to image the homogenizer fiber output into the fiber delivering the beam to the ablation target. A convenient option is to use a fused silica fiber, which is more suitable for high power transmission.
(iv) The use of pairs of pulses to achieve effective removal of tissue from a surgical site, in which the first pulse “conditions” the tissue which can then be more easily removed by a second, often longer pulse. This arrangement enables ablation to the accomplished with less damage to the fiber than if an equivalent single pulse were to be used. Such a method is described in U.S. Pat. No. 5,312,396 for “Pulsed Laser System for the Surgical Removal of Tissue” to M. S. Feld et al.
Additionally, a similar procedure using multiple pulses is described in the article by D. Albagli et al entitled “Time dependence of laser-induced surface breakdown in fused silica at 355 nm in the nanosecond regime”, published in SPIE Vo. 1441, Laser induced Damage in Optical Materials, 1990. Using first and second pulses of the pair at two different wavelengths may also be advantageously used.
In an alternative approach, the pulse length of the laser has been extended to more than 100 nsec in order to improve the damage threshold of the fibers, or has been split into at least two pulses with a 100 to 200 nsec delay between them, but this comes at the expense of the ablation efficiency of hard tissues, such us highly calcified lesions as described in the article by Rod S. Taylor et al entitled “Dependence of the XeCl laser cut rate of plaque on the degree of calcification, laser fluence, and optical pulse duration” published in “Lasers in Surgery and Medicine” Volume 10, Issue 5, pages 414-419, 1990.
However, all of the above mentioned methods have disadvantages, particularly in terms of the limited improvement in energy density carrying capacity that can be achieved for the optical fiber setup used, and/or the system energy throughput, and/or damage to the fiber tip when in contact with tissue.
There therefore exists a need for a method and apparatus for performing ablative surgical methods using fiber optical delivery of the ablation energy, which overcomes at least some of the disadvantages of prior art systems and methods.
In addition to the need for new systems for enabling the ablation process, there is a growing need for the specific procedure of removing pacemaker and defibrillator leads in patients, due to such reasons as lead fracture or abrasion of the insulation causing shorting and infections. Approximately 5 million leads are implanted worldwide and it is estimated that 4-7% will have to be removed at some time during the patient's lifetime. It is estimated that over 100,000 leads were extracted in the US and Europe in 2010.
In Lead Extraction procedures, known hereinafter as LE, the most critical point in the procedure is reached when the lead at a bend in the vein has to be debulked. When the electrode separation procedure is performed, there is a risk of perforation of the vein by the catheter, and in severe cases, this can even result in death of the patient. Rates of 1% death cases or even higher are reported using active dilators.
Laser ablation and mechanical based cutters are widely used solutions for atherectomy procedures in order to open or partially open blockages inside blood vessels. One of the methods of reducing the danger of the vessel wall perforation is by using a system having parameters which preferentially cut or ablate the atheroma tissue over the wall of the blood vessel. If the cutting or ablating effect is significantly more effective on the atheroma material than on the artery or vein wall material, and the procedure is executed under conditions which fall safely below the threshold at which damage may be caused to the vessel wall, there will be less likelihood that the artery or vein wall will be cut during the debulking procedure. In the prior art, in an article entitled “Preferential Light Absorption in Atheromas in Vitro—Implications For Laser Angioplasty” by M. R. Prince et al, published in Journal of Clinical Investigation Vol. 78(1): pages 295-302, July 1986, it has been shown that atheromas indeed absorb more than the normal aorta between 420 and 530 nm. However, this was not found to be so in the UV, where at the widely used 308 nm wavelength, the absorption by the aorta is higher than that of atheroma. However, since use of the 420-530 nm range, with its advantageous ablation selectivity, has an inherent disadvantage in the potential thermal damage caused by the larger energies needed for efficient ablation and deeper penetration, it is preferable to use a method for selective ablation which uses laser radiation within the UV region.
However, it has also been found, as described in the article entitled “Laser Ablation of Atherosclerotic Blood Vessel Tissue Under Various Irradiation Conditions” by R. O Esenaliev et al, published in IEEE Transactions on Biomedical Engineering. Vol. 36, no. 12. Pages 1188 to 1194 (December 1989), that for wavelengths in the UV (355 nm and 266 nm), no difference in the optical attenuation coefficients to short pulses, has been found between the normal wall and fibrous plaque areas of atherosclerotic blood vessels. Therefore, other prior art methods, such as shown in the article entitled “Selective Absorption of Ultraviolet Laser Energy by Human Atherosclerotic Plaque Treated with Tetracycline” by D. Murphy-Chutorian et al, published in the American Journal of Cardiology, Vol. 55, pages 1293-1297, 1985, have suggested the use of sensitizers such as tetracycline, to increase the absorption in the plaque. Tetracycline binds strongly to the plaque and has strong absorption in the UV. The problem with such methods for use in clinical treatments is that tetracycline is an antibiotic, and needs additional regulation and tests to ensure absence of side effects.
There therefore also exists a need for a method and apparatus for safely performing lead extraction, using fiber optical delivery of the ablation energy, which overcomes at least some of the disadvantages of prior art systems and methods. Similarly, there is a need for atherectomy tools for debulking of atheroma in blood vessels that reduce the risk of vessel perforation or dissection and debulking of enlarged glands in Benign Prostatic Hyperplasia (BPH) while reducing the risk of capsule injury.
Laser catheters should be calibrated prior to the operation in order to verify the fluence and the repetition rate of the laser energy that is emitted from the catheters.
The prior art deals with methods of calibration of catheters in which the catheter is pulled out of its packaging, coupled to the laser system, the distal tip is held by a housing in front of a detector, the laser is operated and the energy is measured by the detector as described in U.S. patent Ser. No. 11/946,376 for “Laser catheter calibrator” to Tom Dadisman.
Since the catheters are sterilized before use, this method can involve risk of moving the distal tip of the catheter out of the sterilized area in the operation room.
There therefore also exists a need for a method and apparatus for internal calibration of the laser system and for detecting a failure of the system and/or the catheter.
The disclosures of each of the publications mentioned in this section and in other sections of the specification, are hereby incorporated by reference, each in its entirety.
The present disclosure describes new exemplary systems for enabling the coupling and transmission of very high energy pulses having a very short pulse width, preferably from a solid state Q Switched laser emitting in UV, into optical fibers for use in ablation procedures, which enable substantially higher energy pulses to be transmitted than in the systems described in the prior art. In prior art systems, a laser having as high a quality output as possible is generally used, in keeping with the mantra that in order to achieve high coupling efficiency and better beam quality without “hot spots”, a laser having the mode closest to a single mode output should be used, generally as close as possible to a diffraction limited, Gaussian mode. This is the accepted logic in the use of laser beams for cutting or spot ablation, as indicated for instance in the above-mentioned U.S. Pat. No. 5,312,396, where it is stated, in extolling their suitability for the purpose, that the Nd:YAG lasers used “have good beam quality”. Similarly, in the above referenced article by T. Schmidt-Uhlig et al, it is stated that the pulses of the Q-switched frequency doubled Nd:YAG laser used in their system had “a nearly guassian (sic) temporal and spatial profile”. The same design philosophy applies through most of the prior art high pulse energy, fiber-delivered surgical ablation systems. Similarly, the article by B. Richou et al entitled “Delivery of 10-MW Nd:YAG laser pulses by large-core optical fibers: dependence of the laser-intensity profile on beam propagation” published in Applied Optics Vol. 36, No. 7 (1997), reported higher (230 mJ) transmission of a pulsed Nd:YAG near-Gaussain beam compared to a flat-hat beam (130 mJ). The individual fibers used in the fiber bundles of the systems of the present application generally have core diameters of less than 200 microns, and preferably less than 100 microns, wherein the energy transmitted is in the order of 1-2 mJ with pulse length of 10 ns cannot lead to self-focusing.
However, the system design used in the present application, uses the fact that it is precisely because of the high quality mode structure of such lasers that the serious problems of coupling and transmission through the optical fiber arise, even when dealing with fibers with small diameter such as 100 micron core fibers.
The presently described system differs from these prior art systems in that a source laser outputting multiple transverse modes is used, thereby having a highly multimode output.
The cavity should also advantageously be a stable resonator cavity. Such a laser a priori outputs a beam with low spatial coherence, and therefore reduces the prevalence to damage in the bulk of the fiber due to interference phenomena. Such a laser outputs a beam which is significantly closer to having a uniform beam profile, known as a top-hat configuration, than the prior art, high quality lasers generally used in such systems. In order to improve the immunity from fiber damage even more, prior art homogenization, beam manipulation methods can also advantageously be applied to such a flat-topped beam, with accordingly improved performance. The transmission of such pulses down the fibers results in a higher damage threshold than when using high quality laser pulses, and it has been found possible to transmit pulses having higher energy density, than those of prior art systems, before fiber damage sets in. It is believed that this phenomenon is related to the absence of meaningful interaction between discrete parts of the beam across its profile, which could generate hot spots or interference. However, it is to be understood that the invention is claimed independently of the real reason for its physical operation. It should be noted that since the catheters of the present disclosure utilize a bundle of fibers, and the energy of the individual laser pulses is transmitted through a bundle of fibers and not a single fiber, references to single fibers within this disclosure is generally intended to mean a single fiber out of the bundle of fibers, and is not intended to mean transmission through solely a single fiber.
The mode quality of a laser output beam can be characterized by the beam size and beam divergence. The smaller the divergence for a beam of given size and wavelength, the higher the beam quality. One parameter used for characterizing the beam mode quality is the M2 parameter. The M2 parameter of the beam mode output by the laser is used in the present application to characterize the beam properties for achievement of very high pulse energy densities for such pulses in the nanosecond range. It is to be understood however that use of the M2 parameter is only one way of characterizing beam quality, and the invention of the present disclosure is not intended to be limited by use of this measure.
The M2 parameter is related to the ratio of the output beam size and the beam divergence by the following relationship:
where D=the beam diameter,
A pure diffraction-limited beam would have an M2 parameter of 1, while practical, high-efficiency, commercial lasers for use in surgical or precision industrial applications generally have an M2 parameter in the low single digit range.
The M2 parameter can also be defined for a beam at any point along its optical path, by inserting a focusing lens at that point and measuring the size of the focal spot obtained. Intuitively, the tighter the focal spot, the better the mode quality of the beam at that point, and the lower the M2 parameter. The M2 parameter in that case is given by the following relationship:
where D is now the beam diameter at the point of insertion of the lens,
It is to be understood throughout this disclosure that the M2 parameter used is calculated according to the appropriate one of these formula, depending on whether the measurement relates to the laser output beam, or to a beam downstream in the optical path.
The systems and methods described in the present disclosure differ from those described in the prior art in that the laser used for transmission down the fiber and for ablation at the treatment site is selected to have a highly multimode beam output, preferably a third harmonic Nd:YAG laser, such that the M2 parameter of the output beam should be at least of the order of a few tens, typically at least 30, and optimally up to 70 or even more, such as greater than 100. The M2 of the laser may be greater than 10, but the M2 of the system, including the optics is greater than 70 and preferably more than 200. Such beams therefore behave in a very distinct manner from those described in the prior art, and allow transmission of pulses having pulse energy densities at least twice as much, and even more, than the pulses available from prior art ablation systems using high beam quality lasers. Additional optical means may be added, such as a micro-lens array, to further increase M2 and to increase pulse energy density transmitted reliably for a large number of pulses through fibers typically with 100 micron core or less.
Details of typical performance of such systems are to be found hereinbelow in the Detailed Description section.
The present disclosure furthermore describes new exemplary systems for enabling selective removal of undesired tissue within a blood vessel, while minimizing the risk of damaging the blood vessel itself, based on the use of the ablative properties of short laser pulses of 320-400 nm laser wavelength, with selected parameters of the mechanical walls of the tubes constituting the catheter, of the laser fluence and of the force that is applied by the catheter on the tissues. As stated hereinabove, it was previously believed that the selectivity characteristics of a given tissue without the existence of sensitizers could not be determined using UV radiation, since normal aorta and atheromatous tissues share numerous common molecules whose absorption bands are all in the UV region, whether at 355 nm or at 308 nm. Although the dissociation energy of many organic molecular bonds is typically higher than the photon energy of the 355 nm wavelength (3.5 eV), this does not apply to the 308 nm excimer laser wavelength, whose photon energy is higher (4 eV). Thus, it is believed that the dominant ablation mechanisms at the 355 nm wavelength is photomechanical. In contrast, at the shorter, 308 nm wavelength of the excimer laser, and obviously at even shorter wavelengths, photochemical processes, in which chemical bonds are dissociated by the laser radiation, are more relevant. Because of this difference in the interaction mechanism with the target tissue, this selection of wavelength, together with the other selected parameters, is believed to have a central influence on the success of the presently described catheters. Thus, by using the correctly selected parameters, ablation of the blood vessel walls is far less likely to occur than for the atheroma, because the blood vessel walls have greater elasticity than the atheroma, and therefore withstand the photomechanical mechanisms operating on them much better than the atheroma, which is more readily broken up by such photomechanical influences.
It is also possible that in addition to the operated wavelength aspects, since shock waves plays a major role in the photomechanical ablation mechanism, a reduction in the pulse duration (i.e. higher peak power) may lead to an increased efficiency of the process.
However it is to be emphasized that the present application relates to the catheters described therein, regardless of the physical mechanisms on which the success of their operation is based, and the application is not intended to be limited by any proposals regarding possible mechanisms by which the catheters fulfill their function.
According to one exemplary catheter system of the present disclosure, a third harmonic Nd:YAG laser outputting at 355 nm is coupled to a hybrid catheter, which incorporates a bundle of optical fibers receiving the laser illumination, and at least one blunt-ended tubular structure whose distal edge is located on an essentially single surface with the output facets of the optical fibers, to interact with the atheromatous tissue within the blood vessel. Different configurations are available for LE use and for debulking or opening blood vessels where substantial deposits of atheromatous material is found such as in Peripheral Artery Disease (PAD). In the LE case, a thin annular bundle of fibers is required, with cylindrical walls bounding it on the inner and outer sides of the annulus. The cylindrical walls constitute the blunt-ended tubular structure. On the other hand, in PAD, for removal of deposits across the whole cross-section of a blood vessel, the bundle of fibers essentially covers the whole of the cross section of the catheter, usually with a thin opening in the center of the bundle for a guide wire, but in this case too, the cylindrical walls of the bundle region constitute the blunt ended tubular structure. Throughout this disclosure, these blunt ended tubular structures are termed “blunt mechanical blades”.
Using the LE case as an example, the catheter operates, once within the blood vessel and in contact with the intravascular deposit, by using the laser pulses to ablate a thin layer of the tissue, typically only a few tens of microns deep, making a thin, shallow slit to enable the continued penetration of the blunt mechanical blade in response to the pressure applied distally on the catheter. The blade or blades are therefore constructed to be too blunt to initiate dissection, but with enough of an edge to create the slit to enable deeper catheter penetration into the tissue. The borders of the tissue being ablated, which possesses a transient zone, are mechanically weakened due to the trauma, which facilitates dissection by the blunt blade. The width of the blades, and the ratio of the total area of the cores of the fibers within the fiber optical bundle, from which the ablation energy is emitted, relative to the total cross-sectional area of the tip of the catheter, not including the empty central area, are important parameters which also characterize the catheters of the present disclosure.
The force applied distally on the catheter is an additional parameter whose level is adjusted to ensure that the catheter advances through the atheromatous tissue at a rate commensurate with the rate of laser ablation and mechanical peeling of the hybrid catheter action. The larger the diameter of the catheter, the larger the force that needs to be applied.
The present disclosure furthermore describes new exemplary systems to enable reliable operation of the catheter in a mode of contact with the tissue.
In some embodiments a thin sapphire window or similar is added at the distal end of the fibers. In some embodiments the window is coated with an AR coating.
In other embodiments, the fiber ends at the distal tip are coated with a hard coating. Coating the catheter tip may provide additional performance enhancement. One possible material is diamond. Diamond Like Coatings (DLC) are commonly used in industrial applications where hard, strong, and smooth surfaces are required, for example, to protect from mechanical wear. One of the means to obtain such coatings is through Chemical Vapor Deposition (CVD). Cutting tools are often coated to improve durability. DLC has excellent biocompatibility as it is commonly employed in joint replacements and coronary artery stents.
A diamond coated catheter may have the following advantages. First, the coating hardness may protect the fiber tips from damage due to contact with hard biological media and from the resulting shockwaves from laser ablation. Second, the smoothness (low friction) and simultaneous nano-roughness may be advantageous to allow progression of the catheter and/or enhanced material removal by scraping. Third, the high thermal conductivity may help to distribute heat from absorption of the laser pulses in the tissue.
DLC's are generally not thought suitable for visible wavelengths due to their high absorption. However, when considering the optimal layer thickness required for maximum UV light (355 nm) transmission, a DLC coating with an index of 2.4 would only need to be about 74 nm thick when applied to fused silica in order to obtain a minimum reflection of 3.7%. Absorption of the material should be minimal with such a low thickness. Furthermore, transparent diamond coating can used such as described in the article of E. Pace et al entitled: “Fast stable visible-blind and highly sensitive CVD diamond UV photodetectors for laboratory and space applications” published in “Diamond and Related Materials”, Volume 9, Issues 3-6, Pages 987-993 (April-May 2000). Several manufacturers have applied DLC coatings to glass, including, for example, Jenoptik and Reynard Corporation which produces Clear DLC with enhanced visible light transmission.
Another limitation of use of CLD is the high index of refraction which leads to very high “Fresnel Loses”. A potential way to deal with those loses is to add an AR coating, but this is problematic in the current embodiment due to a number of reasons:
The AR coating can't withstand very high power at the fiber tip. In addition, it needs to be made from biocompatible materials to allow close contact with tissue. Furthermore, the AR coating is subject to mechanical abrasion when in contact with tissue.
Thus, according to the present invention, a diamond layer is used as an AR film wherein its thickness is selected to reduce reflection loses in order to save energy and avoid back reflection into the fiber that can damage it. The thickness can be determined according to the rules used in antireflection coatings such as quarter wavelength, 5/4 wavelength or other combinations according to the angle of emitted light (NA). The thickness can also be determined in such a way that a 355 nn wavelength will be transmitted while another wavelength in the visible are will be reflected. For example, the hard coating at the exit facet can be such that transmits the 355 nm out of the catheter by using a thickness of 9/4 wavelength wherein the wavelength is 355 nm (and corrected according to the refraction index) so that the same layer will be 3/2 of the wavelength at 532 nm (and corrected according to the refraction index) and result in effective back reflection from the fiber end facet for calibration of energy delivered by the system, wherein the 532 nm and 355 nm are generated by the same laser and transmitted through the same coupling optics and catheter. This enables effective calibration before the procedure and serve as on-line calibration and quality control of the catheter throughout the procedure. By mode of example, if the index of refraction is 2.4, a layer with the thickness of 332.8 nm is equivalent to 9/4 wavelengths of 355 nm (in vacuum) and to 1.5 wavelengths of 532 nm (in vacuum). Other embodiments are possible that are optimized for the incident of laser rays transmitted through the fiber that can get up NA of 0.22.
In other implementations, the laser pulse is split into at least two pulses with a delay between pulses of less than 15 nsec delay in order to protect the distal facets of the fibers without significant impact on ablation efficiency. Details of such system can be found below in the detailed description section.
In alternative implementations means to facilitate the flushing of the tip with saline throughout the procedure are described. Details of typical performance of such systems are to be found hereinbelow in the Detailed Description section.
The present disclosure furthermore describes new exemplary systems to enable effective and convenient apparatus for calibration of laser system delivering energy through the fibers. Details of typical performance of such systems are to be found hereinbelow in the Detailed Description section.
There is thus provided in accordance with an exemplary implementation of the devices described in this disclosure, a laser device for ablating a region within a luminar vessel, comprising a pulsed laser, and at least one optical fiber coupled to said laser by means of a coupling optic, wherein the laser has a multimode output such that its M2 parameter is larger than 30. The M2 parameter may be larger than 70 or even 100.
According to another implementation of such devices, there is provided a laser device for ablating a region within a luminar vessel, or other lumens in the body, comprising a pulsed laser emitting in the ultra violet region of the spectrum, and at least one optical fiber coupled to said laser by means of a coupling optic, wherein the laser beam has a multimode profile as measured by the spot size of the beam focused by a lens of known focal length, such that the beam has an M2 parameter of at least 30. The M2 parameter may be larger than 70 or even 100.
In either of these two implementations, the at least one optical fiber may have a core of less than 200 microns diameter. Additionally, the coupling optics may comprise any one or more of a micro lens array, a diffractive optical element, a holographic diffuser, a light pipe rod, and a large core optical fiber. In some implementations, M2 parameter of the laser may be larger than 10 or alternatively greater than 30 but the M2 of the laser together with the above mentioned elements is larger than 70 and preferably greater than 200.
The pulsed laser may advantageously be a Nd:YAG, solid state laser, the laser wavelength may be 355 nm, the laser pulse width may be less than 15 nsec and the pulse laser repetition rate may be greater than 10 Hz. In the latter case, the laser is such that a fluence of at least 60 mJ/mm2 can be delivered through the optical fiber for more than one minute. According to further implementations, the fluence delivered through the optical fiber for more than one minute may be at least 200 mJ/mm2 or even 300 mJ/mm2.
There is thus provided in accordance with an exemplary implementation of the devices described in this disclosure, a device for selective cutting within blood vessels, wherein the device comprises:
(i) a pulsed laser emitting in the wavelength range of 320 to 400 nm, and being coupled to a plurality of optical fibers, such that a flux of energy is emitted from the fibers, and
(ii) tubes acting as boundaries to the plurality of fibers, each of the tubes having a blunt distal edge in the same axial plane as the output end of the plurality of fibers, such that when a distal force is applied to the device, the blunt distal edges push through atheromatous material in the blood vessel in the region where the flux of energy is emitted from the fibers,
wherein the ratio of the total core area from which the flux of energy is emitted to the total distal tip area of the device is at least 25%.
In such a device, the ratio may be in the range of 30% to 40%. Additionally, the laser may advantageously be a third harmonic Nd:YAG laser emitting at 355 nm.
In any of the above described devices, the flux may be at least 50 mJ/mm2 or it may be in the range of 50 to 80 mJ/mm2, or even in the range of 65 to 80 mJ/mm2.
Additionally, the plurality of fibers of the above described device may be a bundle of fibers. In such a case, the overall width of each of the tubes and the fibers should be less than 400 μm and more than 200 μm.
Furthermore, according to yet more implementations of such devices, dyes or substrates may be used to enhance absorption at desired wavelengths. The dye may be tetracycline and the desired wavelength 355 nm.
Another example implementation can involve a system for ablating a region of a tissue, comprising:
(i) a laser emitting a beam of laser pulses, the beam being coupled by means of coupling optics to at least one optical fiber, such that a flux of energy is emitted from the at least one fiber, the at least one fiber having an input facet and an output facet,
(ii) a beam splitter disposed between the laser and the at least one fiber, such that the beam can pass undeflected through the beam polarizer to the at least one fiber, for transmission to the region of tissue, and
(iii) a detector disposed at the beam splitter in a position normal to the direction at which the beam passed undeflected through the beam splitter,
wherein the detector receives a predetermined fraction of the beam reflected from at least one of the input facet and the output facet of the at least one optical fiber, such that the flux of energy passing through the at least one optical fiber can be determined.
Such a system may further comprise
(i) a linear polarizer disposed in the optical path of the beam, such that the beam has a predetermined linear polarization before impinging on the beam splitter, and
(ii) a quarter wave plate disposed between the beam splitter and the input facet of the at least one fiber, such that the predetermined fraction of the beam reflected from at least one of the input facets and the output facets has a linear polarization orthogonal to that of the beam inputting the at least one fiber, such that the beam splitter directs the predetermined fraction towards the detector.
In either of the latter two cases, one of the input and output facets may have an anti-reflective coating, such that the predetermined fraction of the reflected beam is limited to that facet which is uncoated.
The present invention will be understood and appreciated more fully from the following detailed description, taken in conjunction with the drawings in which:
Reference is now made to
Although the laser 10 emits a well-mixed multimode beam, the laser beam is input to a beam homogenizing and/or coherence manipulation unit 14, in order to mix the multiple modes of the output beam 11 even more, such that the fiber has an even higher damage threshold than would be obtained with the multimode output from the laser alone. This unit 14 can be any one or more of a homogenizing plate, a diffractive optical element, a holographic element, a micro-lens array, or a homogenizer optical fiber bent to ensure additional mode mixing during propagation of the pulses down it. A coupling lens 12 is then used for coupling the laser beam into the optical fiber bundle 13. Although the individual fibers could have a core size of less than 200 microns, the optical fiber bundle includes a large number of these individual fibers, and is thus substantially larger than the diameter of the individual fibers, such that there are no special optical difficulty in coupling such a multimode beam into such small fibers. Although only one coupling lens 12 is shown in
Reference is now made to
The beam from the highly multimode laser 10, is transmitted through a half wave plate 27 and then to a polarization beam splitter 28 in order to split the laser beam into two component parts—S-polarized and P-polarized. In the example shown in
Furthermore, the laser beam may split into more than two channels, to even further reduce the potential damage level of the fibers. Additionally, different wavelengths emitted by a laser, such as the second and third harmonics, or the fundamental and third harmonic of the Nd:YAG laser, can be split and combined again. It is also possible to use multiple lasers with a synchronized delay between the pulses.
Reference is now made to
Referring first to
Reference is now made to
In the prior art, methods of calibration of catheters have been described in which the catheter is coupled to the laser system, while the distal tip is held by a housing in front of a detector, and the transmitted energy is measured by the detector while the laser is operated. Since the catheters are sterilized before use, this method can involve the risk of moving the distal tip of the catheter out of the sterilized area in the operation room.
The system shown in
The incident beam from the laser 50 is directed through a beam polarizer 51, which outputs the beam as P-polarized, as marked in
If the entrance facet is coated with an anti-reflective coating, the power measured by the detector 58 is that due only to reflection from the output facet, such that differentiation can be made between reflections from these two facets.
An alternative to the use of an anti-reflective coating on the entrance facet in order to differentiate between the front and the rear facet reflections, it is possible to use a spatial filter disposed between the front facet and the polarizing beam splitter, in order to filter out the reflection from the input facet, which has a smaller divergence angle than the reflection from the output facet, since the numerical aperture of the output reflection is significantly larger. The spatial filter may conveniently be a thin film polarizer (TFP) as illustrated in
According to another exemplary implementation, a cap may be placed over the distal tip of the catheter, with the inside of the cap is coated with reflective coating in order to enhance the signal that is reflected from the distal facets of the fibers.
The cap may be coated with a fluorescent material that changes the wavelength of the output reflected beam, and by use of an optical filter, its separation from the entrance facet reflection is achieved. The cap may be sterilized together with the catheter.
Alternatively, the cap may also be covered with material, polyamide for example, that gives a vocal indication when energy above specified level strikes it. Alternatively, the cup can be covered with material that changes it color when exposed to the radiation of the laser.
The above-described calibration procedure can be performed while the fiber is rolled up inside its packaging, keeping the bend radius of the fiber known and constant, so that the percent of energy reflected back from the output facet does not change.
In some other embodiments, the entrance facet is not coated, and the detector will measure both the energy reflected from the input and output facets.
In some embodiments, the system can be internally calibrated, without connecting the catheter, wherein there is a lid that is moved aside when the catheter is connected, and is closed when the catheter is moved out. This lid is mirror coated at the side that is pointing to the laser, and the energy reflected from this mirror coating is folded by the polarized beam splitter and can be measured in the detector.
The described method of calibrating such catheters also enables real time monitoring of the ablation process, by measuring the reflected energy in the system detector during the procedure and informing the user about energy degradation due to fiber damage.
Reference is now made to
Reference is now made to
Reference is now made to
While the present invention uses example from blood vessels, the utility is relevant for other medical indications requiring controlled resection of tissue such as Barrett's esophagus, flat polyps' removal in the intestine or in urology and gynecology applications such as debulking in BPH.
It is appreciated by persons skilled in the art that the present invention is not limited by what has been particularly shown and described hereinabove. Rather the scope of the present invention includes both combinations and subcombinations of various features described hereinabove as well as variations and modifications thereto which would occur to a person of skill in the art upon reading the above description and which are not in the prior art.
This application is a continuation of, claims the benefit of and priority to, previously filed U.S. patent application Ser. No. 15/309,193 filed on Nov. 6, 2016, which is a national phase of International Patent Application No. PCT/IL2015/050529 filed May 18, 2015, which claims priority to U.S. Provisional Patent Application No. 61/994,904 filed on May 18, 2014 and U.S. Provisional Patent Application No. 62/006,389 filed on Jun. 2, 2014. The disclosures of each of the aforementioned international, non-provisional, and provisional patent applications are hereby incorporated by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
4830460 | Goldenberg | May 1989 | A |
4844062 | Wells | Jul 1989 | A |
4919508 | Grace et al. | Apr 1990 | A |
4955882 | Hakky | Sep 1990 | A |
4975925 | Derrickson | Dec 1990 | A |
4998794 | Holzman | Mar 1991 | A |
5016964 | Donnelly | May 1991 | A |
5060557 | Dunn | Oct 1991 | A |
5157750 | Grace et al. | Oct 1992 | A |
5250045 | Bohley | Oct 1993 | A |
5263952 | Grace et al. | Nov 1993 | A |
5267993 | Grace et al. | Dec 1993 | A |
5312396 | Feld | May 1994 | A |
5315614 | Grace et al. | May 1994 | A |
5321783 | Nielson et al. | Jun 1994 | A |
5350377 | Winston et al. | Sep 1994 | A |
5383199 | Laudenslager et al. | Jan 1995 | A |
5395351 | Fox et al. | Mar 1995 | A |
5400428 | Grace | Mar 1995 | A |
5415653 | Wardle et al. | May 1995 | A |
5423806 | Dale et al. | Jun 1995 | A |
5429604 | Hammersmark et al. | Jul 1995 | A |
5429617 | Hammersmark et al. | Jul 1995 | A |
5456680 | Taylor et al. | Oct 1995 | A |
5470330 | Goldenberg et al. | Nov 1995 | A |
5484433 | Taylor et al. | Jan 1996 | A |
5486170 | Winston et al. | Jan 1996 | A |
5514128 | Hillsman et al. | May 1996 | A |
5643251 | Hillsman et al. | Jul 1997 | A |
5720894 | Neev | Feb 1998 | A |
5810662 | Van Becelaere | Sep 1998 | A |
5817144 | Gregory | Oct 1998 | A |
5824026 | Diaz | Oct 1998 | A |
5836940 | Gregory | Nov 1998 | A |
5836946 | Diaz et al. | Nov 1998 | A |
5916210 | Winston | Jun 1999 | A |
5951482 | Winston et al. | Sep 1999 | A |
5976124 | Reiser | Nov 1999 | A |
5989243 | Goldenberg | Nov 1999 | A |
6013072 | Winston et al. | Jan 2000 | A |
6048349 | Winston et al. | Apr 2000 | A |
6053809 | Arceneaux | Apr 2000 | A |
6063093 | Winston et al. | May 2000 | A |
6106515 | Winston et al. | Aug 2000 | A |
6193676 | Winston et al. | Feb 2001 | B1 |
6206898 | Honeycutt et al. | Mar 2001 | B1 |
6210400 | Hebert et al. | Apr 2001 | B1 |
6228076 | Winston et al. | May 2001 | B1 |
6394976 | Winston et al. | May 2002 | B1 |
6439944 | La Fata | Aug 2002 | B1 |
6440125 | Rentrop | Aug 2002 | B1 |
6463313 | Winston | Oct 2002 | B1 |
6485485 | Winston et al. | Nov 2002 | B1 |
6539944 | Watson | Apr 2003 | B1 |
6547779 | Levine et al. | Apr 2003 | B2 |
6554824 | Davenport et al. | Apr 2003 | B2 |
6611720 | Hata | Aug 2003 | B2 |
6663621 | Winston et al. | Dec 2003 | B1 |
6673064 | Rentrop | Jan 2004 | B1 |
6701044 | Arbore et al. | Mar 2004 | B2 |
6716210 | Lin | Apr 2004 | B2 |
6752800 | Winston et al. | Jun 2004 | B1 |
6772014 | Coe et al. | Aug 2004 | B2 |
6775447 | Nicholson et al. | Aug 2004 | B2 |
6842639 | Winston et al. | Jan 2005 | B1 |
6852109 | Winston et al. | Feb 2005 | B2 |
6951554 | Johansen et al. | Oct 2005 | B2 |
6967767 | Nicholson | Nov 2005 | B2 |
6970732 | Winston et al. | Nov 2005 | B2 |
6986764 | Davenport et al. | Jan 2006 | B2 |
7050692 | Harlan et al. | May 2006 | B2 |
7083610 | Murray et al. | Aug 2006 | B1 |
7167622 | Temelkuran et al. | Jan 2007 | B2 |
7257302 | Fermann et al. | Aug 2007 | B2 |
7288087 | Winston et al. | Oct 2007 | B2 |
7303533 | Johansen et al. | Dec 2007 | B2 |
7379648 | Brooks et al. | May 2008 | B1 |
7391561 | Di Teodoro et al. | Jun 2008 | B2 |
7430352 | Di Teodoro et al. | Sep 2008 | B2 |
7450618 | Dantus et al. | Nov 2008 | B2 |
7479147 | Honeycutt et al. | Jan 2009 | B2 |
7483204 | Harter | Jan 2009 | B2 |
7499756 | Bowe et al. | Mar 2009 | B2 |
7503914 | Coleman et al. | Mar 2009 | B2 |
7513886 | Konstantino | Apr 2009 | B2 |
7519253 | Islam | Apr 2009 | B2 |
7563262 | Winston et al. | Jul 2009 | B2 |
7567596 | Dantus et al. | Jul 2009 | B2 |
7572254 | Hebert et al. | Aug 2009 | B2 |
7651503 | Coe et al. | Jan 2010 | B1 |
7666161 | Nash et al. | Feb 2010 | B2 |
7724787 | Murison et al. | May 2010 | B2 |
7787506 | Jiang et al. | Aug 2010 | B1 |
7809222 | Hartl et al. | Oct 2010 | B2 |
7811281 | Rentrop | Oct 2010 | B1 |
7834331 | Ben-Yakar et al. | Nov 2010 | B2 |
7846153 | Hebert et al. | Dec 2010 | B2 |
7924892 | Chuang et al. | Apr 2011 | B2 |
7927784 | Simpson | Apr 2011 | B2 |
7929579 | Hohm | Apr 2011 | B2 |
7951094 | Johansen et al. | May 2011 | B2 |
7959608 | Nash et al. | Jun 2011 | B2 |
7975528 | Nash et al. | Jul 2011 | B2 |
7993359 | Atwell et al. | Aug 2011 | B1 |
8059274 | Splinter | Nov 2011 | B2 |
8062226 | Moore | Nov 2011 | B2 |
8073019 | Liu et al. | Dec 2011 | B2 |
8097012 | Kagarise | Jan 2012 | B2 |
8100893 | Dadisman | Jan 2012 | B2 |
8104463 | Taylor | Jan 2012 | B2 |
8114429 | Michal et al. | Feb 2012 | B2 |
8128951 | Michal et al. | Mar 2012 | B2 |
8182474 | Winston et al. | May 2012 | B2 |
8189971 | Vaissie et al. | May 2012 | B1 |
8202238 | Wells | Jun 2012 | B2 |
8238386 | Limpert et al. | Aug 2012 | B2 |
8257722 | Michal et al. | Sep 2012 | B2 |
8300669 | Dantus et al. | Oct 2012 | B2 |
8317779 | Mirkov et al. | Nov 2012 | B2 |
8350183 | Vogel et al. | Jan 2013 | B2 |
8353899 | Wells | Jan 2013 | B1 |
8414568 | Harlan | Apr 2013 | B2 |
8422134 | Wu | Apr 2013 | B2 |
8428747 | Coe et al. | Apr 2013 | B2 |
8465480 | Winston et al. | Jun 2013 | B2 |
8491925 | Michal et al. | Jul 2013 | B2 |
8512326 | Shadduck et al. | Aug 2013 | B2 |
8545488 | Taylor et al. | Oct 2013 | B2 |
8563023 | Michal et al. | Oct 2013 | B2 |
8587864 | Harter | Nov 2013 | B2 |
8628519 | Taylor et al. | Jan 2014 | B2 |
8636726 | Wells | Jan 2014 | B1 |
8657785 | Torrance et al. | Feb 2014 | B2 |
8673332 | Michal et al. | Mar 2014 | B2 |
8696695 | Patel et al. | Apr 2014 | B2 |
8702773 | Keeler | Apr 2014 | B2 |
8728066 | Shadduck et al. | May 2014 | B2 |
8734825 | Michal et al. | May 2014 | B2 |
8758333 | Harlan | Jun 2014 | B2 |
8767287 | Clowes et al. | Jul 2014 | B2 |
8808074 | Kim | Aug 2014 | B2 |
8855151 | Harter et al. | Oct 2014 | B2 |
8861075 | Dantus et al. | Oct 2014 | B2 |
8881735 | Mitchell et al. | Nov 2014 | B2 |
8920402 | Nash et al. | Dec 2014 | B2 |
8953648 | Ishaaya et al. | Feb 2015 | B2 |
8955376 | Alvarez et al. | Feb 2015 | B2 |
8961551 | Taylor | Feb 2015 | B2 |
8979828 | Fix | Mar 2015 | B2 |
8998936 | Alvarez et al. | Apr 2015 | B2 |
9028520 | Taylor et al. | May 2015 | B2 |
9034362 | Michel et al. | May 2015 | B2 |
9044829 | Crist et al. | Jun 2015 | B2 |
9050127 | Bonnette et al. | Jun 2015 | B2 |
9066736 | Islam | Jun 2015 | B2 |
9066742 | Splinter | Jun 2015 | B2 |
9125562 | Spencer et al. | Sep 2015 | B2 |
9132211 | Michal et al. | Sep 2015 | B2 |
D740946 | Szabo | Oct 2015 | S |
9162038 | Rottanberg et al. | Oct 2015 | B2 |
D742520 | Szabo | Nov 2015 | S |
D742521 | Szabo | Nov 2015 | S |
D742522 | Szabo | Nov 2015 | S |
9198968 | Michal et al. | Dec 2015 | B2 |
9216056 | Datta et al. | Dec 2015 | B2 |
9220523 | Taylor et al. | Dec 2015 | B2 |
D748266 | Szabo | Jan 2016 | S |
9238122 | Malhi et al. | Jan 2016 | B2 |
9254175 | Winston et al. | Feb 2016 | B2 |
9283039 | Harlan | Mar 2016 | B2 |
9283040 | Hendrick et al. | Mar 2016 | B2 |
9287677 | Clowes et al. | Mar 2016 | B2 |
9289173 | Splinter | Mar 2016 | B2 |
9289226 | Taylor | Mar 2016 | B2 |
9291683 | Grace | Mar 2016 | B2 |
9295373 | Torrance et al. | Mar 2016 | B2 |
D753289 | Shimon | Apr 2016 | S |
D753290 | Shimon | Apr 2016 | S |
9308047 | Taylor et al. | Apr 2016 | B2 |
9320530 | Grace | Apr 2016 | B2 |
9333007 | Escudero et al. | May 2016 | B2 |
9339337 | Fix | May 2016 | B2 |
9345508 | Hendrick | May 2016 | B2 |
9345510 | Patel et al. | May 2016 | B2 |
9358042 | Magee | Jun 2016 | B2 |
9368931 | Bragagna et al. | Jun 2016 | B2 |
9408655 | Sauro et al. | Aug 2016 | B2 |
9408998 | Alvarez et al. | Aug 2016 | B2 |
9413696 | Bowe et al. | Aug 2016 | B2 |
9421035 | Hendrick | Aug 2016 | B2 |
9421065 | Splinter et al. | Aug 2016 | B2 |
9456872 | Hendrick et al. | Oct 2016 | B2 |
D775728 | Cavada et al. | Jan 2017 | S |
9566116 | Winston et al. | Feb 2017 | B2 |
9603618 | Grace et al. | Mar 2017 | B2 |
9603973 | Michal et al. | Mar 2017 | B2 |
9622819 | Mitchell et al. | Apr 2017 | B2 |
9623211 | Hendrick et al. | Apr 2017 | B2 |
9636482 | McDaniel et al. | May 2017 | B2 |
9642646 | Patel et al. | May 2017 | B2 |
9649158 | Datta et al. | May 2017 | B2 |
9649159 | Keeler | May 2017 | B2 |
9668765 | Grace et al. | Jun 2017 | B2 |
9668766 | Rottenberg et al. | Jun 2017 | B2 |
9675371 | Shimon | Jun 2017 | B2 |
9675415 | Varghese | Jun 2017 | B2 |
9676167 | Marjanovic et al. | Jun 2017 | B2 |
9678405 | Mironov et al. | Jun 2017 | B2 |
9724122 | Hendrick et al. | Aug 2017 | B2 |
9731098 | Hendrick | Aug 2017 | B2 |
9731113 | Grace et al. | Aug 2017 | B2 |
9757200 | Magee et al. | Sep 2017 | B2 |
9763692 | Bowe et al. | Sep 2017 | B2 |
9770536 | Speck et al. | Sep 2017 | B2 |
9774461 | Zach et al. | Sep 2017 | B2 |
9775969 | Alvarez et al. | Oct 2017 | B2 |
9780518 | Sierra et al. | Oct 2017 | B2 |
9795505 | Yu et al. | Oct 2017 | B2 |
9801650 | Taylor et al. | Oct 2017 | B2 |
9808275 | Taylor | Nov 2017 | B2 |
9808277 | Nash et al. | Nov 2017 | B2 |
9814862 | Alvarez et al. | Nov 2017 | B2 |
9821090 | Triffo | Nov 2017 | B2 |
9827055 | Hendrick et al. | Nov 2017 | B2 |
9844410 | Mitchell et al. | Dec 2017 | B2 |
9848952 | Khanna et al. | Dec 2017 | B2 |
9855100 | Splinter et al. | Jan 2018 | B2 |
9878399 | Liu | Jan 2018 | B2 |
9882342 | Zach et al. | Jan 2018 | B2 |
9883885 | Hendrick et al. | Feb 2018 | B2 |
9884184 | Triffo | Feb 2018 | B2 |
9907614 | Grace et al. | Mar 2018 | B2 |
9907615 | Keeler | Mar 2018 | B2 |
9913688 | Karavitis | Mar 2018 | B1 |
9918729 | Taylor et al. | Mar 2018 | B2 |
9925366 | Grace et al. | Mar 2018 | B2 |
9925371 | Grace | Mar 2018 | B2 |
9931166 | Sauro et al. | Apr 2018 | B2 |
9937005 | Hendrick et al. | Apr 2018 | B2 |
9949753 | Bowe et al. | Apr 2018 | B2 |
9956385 | Ruane | May 2018 | B2 |
9962527 | Laudenslager et al. | May 2018 | B2 |
9980743 | Grace et al. | May 2018 | B2 |
9999468 | Chalfant | Jun 2018 | B2 |
10010657 | Torrance et al. | Jul 2018 | B2 |
10039569 | Hendrick | Aug 2018 | B2 |
10046093 | Michal et al. | Aug 2018 | B2 |
10052129 | Grace et al. | Aug 2018 | B2 |
10079466 | Ishaaya et al. | Sep 2018 | B2 |
10080608 | Datta et al. | Sep 2018 | B2 |
10065883 | Auld et al. | Oct 2018 | B2 |
10092357 | Fix | Oct 2018 | B2 |
10092363 | Magee et al. | Oct 2018 | B2 |
10105533 | Grace | Oct 2018 | B2 |
10111709 | Taylor et al. | Oct 2018 | B2 |
10117970 | Michal et al. | Nov 2018 | B2 |
10135225 | Weichmann | Nov 2018 | B2 |
10136913 | Grace et al. | Nov 2018 | B2 |
10141709 | Ishaaya et al. | Nov 2018 | B2 |
10149718 | Fiser et al. | Dec 2018 | B2 |
10183150 | McDaniel et al. | Jan 2019 | B2 |
10183151 | Alvarez et al. | Jan 2019 | B2 |
10201387 | Grace et al. | Feb 2019 | B2 |
10206745 | Hendrick et al. | Feb 2019 | B2 |
10219819 | Grace et al. | Mar 2019 | B2 |
10236952 | Sadot et al. | Mar 2019 | B1 |
10245107 | Sierra et al. | Apr 2019 | B2 |
10266520 | Grace | Apr 2019 | B2 |
10268792 | Archuleta et al. | Apr 2019 | B2 |
10271904 | Islam | Apr 2019 | B2 |
10265726 | Nguyen et al. | May 2019 | B2 |
10305244 | Sierra et al. | May 2019 | B2 |
10321931 | Aljuri | Jun 2019 | B2 |
10363398 | Gerrans et al. | Jul 2019 | B2 |
20040142654 | Stammer et al. | Jul 2004 | A1 |
20060241495 | Kurtz | Oct 2006 | A1 |
20060264905 | Eskridge et al. | Nov 2006 | A1 |
20090163899 | Burton et al. | Jun 2009 | A1 |
20100069897 | Spikker et al. | Mar 2010 | A1 |
20100191178 | Ross et al. | Jul 2010 | A1 |
20100296531 | Hohm | Nov 2010 | A1 |
20110134523 | Wu | Jun 2011 | A1 |
20130005236 | Kim et al. | Jan 2013 | A1 |
20140263207 | Liu | Sep 2014 | A1 |
20140276682 | Hendrick et al. | Sep 2014 | A1 |
20150038953 | Varghese | Feb 2015 | A1 |
20150359595 | Ben Oren et al. | Dec 2015 | A1 |
20190015157 | Grace | Jan 2019 | A1 |
Number | Date | Country |
---|---|---|
1610855 | Jan 2006 | EP |
3025175 | Jun 2016 | EP |
224434 | Dec 2016 | IL |
Number | Date | Country | |
---|---|---|---|
20200046430 A1 | Feb 2020 | US |
Number | Date | Country | |
---|---|---|---|
62006389 | Jun 2014 | US | |
61994904 | May 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15309193 | US | |
Child | 16655864 | US |